Flu Influenza Vaccine Market 2022-2028

Description

List of Tables

Title:Global Flu Influenza Vaccine Market Size, Share, and Trends Analysis Report, By Vaccine Type (Quadrivalent and Trivalent), By Technology (Egg-Based and Cell Culture), By Age Group (Pediatric and Adult), By Route of Administration (Injection and Nasal Spray), Forecast (2022 to 2028).

The global flu influenza vaccine market is anticipated to grow at a CAGR of 6.9% during the forecast period. The market players are investing in influenza vaccine technology which in turn, is offering an opportunity for market growth. For instance, in August 2021, the Seqirus business of CSL Ltd. Accelerated the development of its next generation of messenger RNA (mRNA) vaccine technology, self-amplifying messenger RNA (sa-mRNA), with the creation of a dedicated sa-mRNA program and senior leadership appointment. Moreover, the rising focus of major pharma companies on developing innovative vaccine solutions will further boost the influenza vaccine market.

The global flu influenza vaccine market is segmented based on type, technology, age group, and route of administration. Based on type, the market is segmented into quadrivalent and trivalent. Based on technology, the market is segmented into egg-based and cell culture. Furthermore, based on age group, it is bifurcated into pediatric and adult. Among these, the adult age group segment was the highest contributor to the influenza vaccine market in 2021 and is expected to remain dominant during the forecast period owing to the increasing geriatric population and the high risk of developing flu among them due to weaker immunity. Whereas based on the route of administration, the market is segmented into injection and nasal spray.

Geographically, the flu influenza vaccine market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The market in the Asia-Pacific region is anticipated to experience the fastest growth during the forecast period owing to the increasing population in major economies such as China and India and the high prevalence of influenza virus among them which has surged the demand and development of influenza vaccines to combat flu diseases. Whereas North America is expected to dominate and hold the highest share owing to the increasing incidence of influenza outbreaks in countries such as the US.

The major market players in the global flu influenza vaccine market include AstraZeneca plc, GlaxoSmithKline plc, and Sanofi S.A., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.

Research Methodology

The market study of the global flu influenza vaccine is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

Financial reports of companies involved in the market.

Whitepapers, research papers, and news blogs.

Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

Global Flu influenza vaccine Research and Analysis by Vaccine Type
Global Flu influenza vaccine Research and Analysis by Technology
Global Flu influenza vaccine Research and Analysis by Age Group
Global Flu influenza vaccine Research and Analysis by Route of Administration

The Report Covers:

Comprehensive research methodology of the global flu influenza vaccine market.
This report also includes a detailed and extensive market overview with key analyst insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global flu influenza vaccine market.
Insights about market determinants that are stimulating the global flu influenza vaccine market.
Detailed and extensive market segments with the regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.

Product Code: OMR2026877

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Recovery Scenario of Global Flu Influenza Vaccine Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
- 3.1.1. Overview
- 3.1.2. Financial Analysis
- 3.1.3. SWOT Analysis
- 3.1.4. Recent Developments
3.2. Key Strategy Analysis

4. Market Segmentation

4.1. Global Flu Influenza Vaccine Market by Vaccine Type
- 4.1.1. Quadrivalent
- 4.1.2. Trivalent
4.2. Global Flu Influenza Vaccine Market by Technology
- 4.2.1. Egg-Based
- 4.2.2. Cell Culture
4.3. Global Flu Influenza Vaccine Market by Age Group
- 4.3.1. Pediatric
- 4.3.2. Adult
4.4. Global Flu Influenza Vaccine Market by Route of Administration
- 4.4.1. Injection
- 4.4.2. Nasal Spray

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
- 5.4.1. Latin America
- 5.4.2. Middle East & Africa

6. Company Profiles

6.1. Abbott Laboratories
6.2. AstraZeneca plc
6.3. Biodiem
6.4. CPL Biologicals Pvt. Ltd
6.5. CSL Limited (Seqirus GmbH)
6.6. Emergent BioSolutions
6.7. F. Hoffmann-La Roche Ltd.
6.8. Gamma Vaccines Pty Ltd.
6.9. GlaxoSmithKline plc
6.10. MedImmune LLC (AstraZeneca plc)
6.11. Merck & Co. Inc. (Merck Sharp & Dohme Corp.)
6.12. Mitsubishi Tanabe Pharma Corporation
6.13. Novartis International AG
6.14. Pfizer Inc.
6.15. Sanofi S.A.
6.16. Sinovac Biotech Ltd.